These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 22940126)

  • 1. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat.
    Cheng D; Cao N; Chen J; Yu X; Shuai X
    Biomaterials; 2012 Feb; 33(4):1170-9. PubMed ID: 22061491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
    Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the surface charge of polyamidoamine dendrimers on cellular exocytosis and the exocytosis mechanism in multidrug-resistant breast cancer cells.
    Zhang J; Li M; Wang M; Xu H; Wang Z; Li Y; Ding B; Gao J
    J Nanobiotechnology; 2021 May; 19(1):135. PubMed ID: 33980270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
    Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
    Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells.
    Wu J; Wang YS; Yang XY; Liu YY; Yang JR; Yang R; Zhang N
    Nanotechnology; 2012 Sep; 23(35):355101. PubMed ID: 22875697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
    Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
    J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
    van Zon A; Mossink MH; Schoester M; Scheper RJ; Sonneveld P; Wiemer EA
    Cancer Res; 2004 Jul; 64(14):4887-92. PubMed ID: 15256459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.